Joan Robbins Email

VP Translational Research . DNAtrix

Current Roles

Employees:
4
Revenue:
$620k
About
DNAtrix is a privately held biotech company developing virus-driven immunotherapies to treat cancer. Its proprietary adenovirus platform is based on an engineered version of the common cold virus that is designed to selectively infect and kill cancer cells while leaving healthy cells unharmed. The company's lead product candidate is DNX-2401, which is expected to enter into a global pivotal Phase 3 clinical study for patients with recurrent glioblastoma. DNX-2401 is also being evaluated in a Phase 1 study for diffuse intrinsic pontine glioma, for which it has received FDA Fast Track and Rare Pediatric Disease designations. A second product candidate, DNX-2440, is entering a Phase 1 clinical study in patients with colorectal and other cancers with liver metastasis. The company's investors include Morningside Ventures and Mercury Fund.
DNAtrix Address
2450 Holcombe Blvd.
Houston, TX
United States
DNAtrix Email

Past Companies

ServareGMP - A Developer of Biologics Against Diseases Harming the Most VulnerableScientific Advisor
DNAtrixVice President Translational Research
WIRB-Copernicus GroupSenior Vice President Biosafety and Gene Therapy

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.